Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease

E4_HYPERURI

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — E79.0 Cause of death: ICD-10 — E79.0 2 out of 7 registries used, show all original rules.	162
4. Check minimum number of events None	162
5. Include endpoints None	162
6. Filter based on genotype QC (FinnGen only)	162

Control definitions (FinnGen only)

Control exclude: E4_METABOLIA

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: E79
Name in latin: Hyperurichaemia sine symptomatibus arthritidis inflammatoriae sive morbi tophacei

NAME	E4_HYPERURI
CONTROL_EXCLUDE	E4_METABOLIA
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	E790
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	E790
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	1098	486	606
Only index persons	956	413	543
Unadjusted period prevalence (%)
Whole population	0.02	0.01	0.02
Only index persons	0.02	0.02	0.02
Median age at first event (years)
Whole population	67.61	70.73	65.06
Only index persons	65.92	68.15	64.22

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	162	58	104
Unadjusted period prevalence (%)	0.04	0.02	0.05
Median age at first event (years)	65.33	62.56	66.88

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
149: Matched controls
1489

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

E79.0

ICD-10 Finland

Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease

+∞

215.4

149

M04AA01

ATC

allopurinol; systemic

15.4

46.4

141

M10.9

ICD-10 Finland

Gout, unspecified

9.8

19.8

202

Kela drug reimbursment

Connective tissue diseases, rheumatoid arthritis and comparable disease

7.5

15.7

N18.9

ICD-10 Finland

Chronic kidney disease, unspecified

9.3

15.5

C03CA01

ATC

furosemide; systemic

4.2

15.0

293

M10.0

ICD-10 Finland

Idiopathic gout

15.7

14.3

H02AB06

ATC

prednisolone; systemic

3.9

13.8

504

212

Kela drug reimbursment

Gout

15.0

13.4

N17.9

ICD-10 Finland

Acute renal failure, unspecified

14.2

12.0

M13.9

ICD-10 Finland

Arthritis, unspecified

7.1

11.6

C10AA05

ATC

atorvastatin; oral

3.4

11.4

388

A46

ICD-10 Finland

Erysipelas

4.7

10.9

108

GD1AA

NOMESCO Finland

Thorax X-ray examination

3.2

10.6

472

NK4XE

NOMESCO Finland

Joint ultrasound examination not elsewhere classified

7.1

10.2

C07AB07

ATC

bisoprolol; oral

3.1

10.0

547

I50.9

ICD-10 Finland

Heart failure, unspecified

4.2

9.7

120

I10

ICD-10 Finland

Essential (primary) hypertension

3.1

9.5

108

680

J01FF01

ATC

clindamycin; systemic

3.3

9.5

246

205

Kela drug reimbursment

Chronic hypertension

3.1

9.5

324

TNX10

NOMESCO Finland

Arthrocentesis, unspecified region, unspecified region

6.3

9.4

JN3AE

NOMESCO Finland

Abdominal ultrasound examination

4.3

9.3

102

P01BA02

ATC

hydroxychloroquine; oral

5.6

9.1

C08CA01

ATC

amlodipine; oral

2.9

8.9

399

A10BH05

ATC

linagliptin; oral

6.8

8.9

NH3BA

NOMESCO Finland

Foot and toes extensive X-ray examination

12.7

8.8

M04AA03

ATC

febuxostat; oral

53.2

8.8

E78.00

ICD-10 Finland

Familial hypercholesterolaemia

53.2

8.8

ND2BA

NOMESCO Finland

Hand and fingers extensive X-ray examination

53.2

8.8

288

Kela drug reimbursment

Febuxostat

29.5

8.6

TPH15

NOMESCO Finland

Insertion of central venous catheter through external or internal jugular vein

6.4

8.5

R06.0

ICD-10 Finland

Dyspnoea

3.3

8.5

192

E86

ICD-10 Finland

Volume depletion

+∞

8.4

M06.0

ICD-10 Finland

Seronegative rheumatoid arthritis

12.7

8.3

L28

ICPC

Limited function/disability (L)

3.5

8.2

144

E78.9

ICD-10 Finland

Disorder of lipoprotein metabolism, unspecified

18.5

8.2

TND11

NOMESCO Finland

Injection of diagnostic or therapeutic substance in joint, wrist or hand

18.5

8.2

E78.01

ICD-10 Finland

Pure hypercholesterolaemia

4.2

8.2

349

Kela drug reimbursment

Febuxostat

35.5

8.2

A10BA02

ATC

metformin; oral

2.9

8.2

290

C10AA01

ATC

simvastatin; oral

2.8

8.1

484

J01DB01

ATC

cefalexin; oral

3.5

8.0

129

961

GD1UA

NOMESCO Finland

Thorax X-ray examination outside radiological department

3.6

8.0

135

L04AX03

ATC

methotrexate; systemic (immunosuppressants)

5.1

7.9

215

Kela drug reimbursment

Diabetes, non-insulin-treated

3.0

7.9

234

103

Kela drug reimbursment

Diabetes, insulin-treated

2.9

7.9

275

A49.9

ICD-10 Finland

Bacterial infection, unspecified

4.4

7.9

FN1AC

NOMESCO Finland

Angiography of heart and/or coronary arteries

3.1

7.7

196

A07EC01

ATC

sulfasalazine; oral, rectal

5.1

7.7

C03DA01

ATC

spironolactone; oral

4.2

7.6

E78.5

ICD-10 Finland

Hyperlipidaemia, unspecified

9.1

7.5

GD1QA

NOMESCO Finland

Supine thorax X-ray examination

3.3

6.9

134

N19

ICD-10 Finland

Unspecified kidney failure

8.5

6.8

H02AB07

ATC

prednisone; oral

3.5

6.7

108

E11.7

ICD-10 Finland

Type 2 diabetes mellitus, with multiple complications

5.4

6.6

G47.3

ICD-10 Finland

Sleep apnoea

2.9

6.5

182

M07.3*L40.5

ICD-10 Finland

Other psoriatic arthropathies

11.8

6.4

AN1

Coronary angiography

3.5

6.3

E66.01

ICD-10 Finland

Obesity due to excess calories

5.7

6.2

E11.9

ICD-10 Finland

Type 2 diabetes mellitus, without complications

2.7

6.2

221

A10AE05

ATC

insulin detemir; parenteral

6.0

6.2

N02BE01

ATC

paracetamol; systemic, rectal

3.4

6.2

134

1077

A10AC01

ATC

insulin (human); parenteral (insulins and analog. for injection, intermediate-acting)

4.7

6.1

J01MA12

ATC

levofloxacin; systemic

2.8

6.1

176

M05.8

ICD-10 Finland

Other seropositive rheumatoid arthritis

5.8

6.0

Mortality – FinRegistry

↥

Association

Association between endpoint E4_HYPERURI and mortality.

Females

Parameter	HR [95% CI]	p-value
E4_HYPERURI	2.552 [1.94, 3.35]	< 0.001
Birth year	0.993 [0.98, 1.0]	0.157

During the follow-up period (1.1.1998 — 31.12.2019), 188 out of 407 females with E4_HYPERURI died.

Males

Parameter	HR [95% CI]	p-value
E4_HYPERURI	2.743 [1.91, 3.95]	< 0.001
Birth year	0.985 [0.98, 0.99]	0.002

During the follow-up period (1.1.1998 — 31.12.2019), 181 out of 494 males with E4_HYPERURI died.

Mortality risk

Mortality risk for people of age

years, who have E4_HYPERURI.

N-year risk	Females	Males
1	0.153%	0.478%
5	1.103%	2.974%
10	3.035%	7.543%
15	5.976%	13.46%
20	10.95%	22.07%

Relationships between endpoints

↥

Index endpoint: E4_HYPERURI – Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

Extremity

rg [CI]

Extremity

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Hyperuricaemia without signs of inflammatory arthritis and tophaceous disease

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

Matched cohort

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints